title: A prospective evaluation of minimal residual disease as risk stratification for CCLG-ALL-2008 treatment protocol in pediatric B precursor acute lymphoblastic leukemia.
abstract: The aim of this prospective study was to evaluate the cut-off value of minimal residual disease (MRD) in predicting the efficacy of CCLG-ALL-2008 or CCLG-2008 treatment protocol on pediatric B-precursor ALL (BP-ALL).
  
  
  
  Three hundred and seventy-nine Chinese pediatric BP-ALL were enrolled in this study between Dec 2008 and Sep 2013 in two stratified cohorts. One hundred and fifty-three patients enrolled between Dec 2008 and Oct 2010 as the first cohort, and 196 patients enrolled from Nov 2010 to Sep 2013 as the second cohort. Clinical and biological characteristics and 5 years EFS, RFS, and OS were analyzed.
  
  
  
  Patients with E2A-PBX1 showed a favorable treatment response with a lower minimal residual disease (MRD) level (< 10-4) at the time point 1 (TP1, p = 0.039) and the highest proportion of the 5-year EFS, RFS, and OS. A high level of MRD was associated with high WBC counts, increased age, BCR-ABL1 fusion gene, MLL rearrangements and adverse karyotypes. In comparison with the first cohort, the second cohort with the MRD assay incorporated prospectively, the standard risk (SR) and the intermediate risk (IR) patients showed a better RFS, EFS, and OS while the high-risk (HR) patients displayed worse RFS, EFS, and OS than those of the first cohort, respectively. Patients with MRD level at either 10-4 or 10-3 showed a similar OS at TP1 or TP2, and patients with MRD level above 10-2 had the worst OS.
  
  
  
  This study indicated that the levels of MRD to be an adequate guide in risk-adapted treatment under the CCLG-ALL-2008 protocol and can be adapted to the future development of advanced clinical protocols.
authors.affiliation: Department of Hematology and Oncology, The Children's Hospital of Soochow University, Suzhou, China. hsy139@126.com.
authors.forename: Y-X
authors.initials: YX
authors.lastname: Hu
authors.forename: J
authors.initials: J
authors.lastname: Lu
authors.forename: H-L
authors.initials: HL
authors.lastname: He
authors.forename: Y
authors.initials: Y
authors.lastname: Wang
authors.forename: J-Q
authors.initials: JQ
authors.lastname: Li
authors.forename: P-F
authors.initials: PF
authors.lastname: Xiao
authors.forename: J
authors.initials: J
authors.lastname: Li
authors.forename: H
authors.initials: H
authors.lastname: Lv
authors.forename: Y-N
authors.initials: YN
authors.lastname: Sun
authors.forename: J-J
authors.initials: JJ
authors.lastname: Fan
authors.forename: Y-H
authors.initials: YH
authors.lastname: Chai
authors.forename: S-Y
authors.initials: SY
authors.lastname: Hu
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002648:Child; D006801:Humans; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D018365:Neoplasm, Residual / Q000235:genetics*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000188:drug therapy*; D011379:Prognosis; D011446:Prospective Studies; D012306:Risk